Menu

Latest Pharma Insights


Progentity completes $125mm Series B round
Molecular diagnostics firm Progenity Inc. (women's health, reproductive medicine, and oncology testing) raised $125mm in a Series B round of equity and debt led by a fund managed by returning backer Athyrium Capital Management.
Strategic Transactions - February 24, 2018
Counsyl completes $80mm late-stage round
DNA screening company Counsyl Inc. (prenatal testing, women's health, and hereditary disorders) completed an undisclosed late-stage round of $80mm from Perceptive Advisors.
Strategic Transactions - February 24, 2018
FOPO nets $282mm for Amicus
Amicus Therapeutics Inc. (therapies for rare metabolic conditions) netted $282mm in its follow-on public offering of 19.35mm common shares at $15.50. The company will use some of the proceeds for global commercialization of migalastat for Fabry's disease, to invest in manufacturing capabilities for its Phase II Pompe disease candidate ATB200, and for additional R&D and commercial activities.
Strategic Transactions - February 24, 2018
Series A lands €16mm for ABAC Therapeutics
Antibiotics developer ABAC Therapeutics raised €16mm ($19.8mm) in its Series A financing led by Pontifax, which was joined by Global Health Science Fund (formed by Quark Venture and GF Securities), Caixa Capital Risc, Debiopharm Innovation Fund (part of Debiopharm Group), and returning shareholder Grupo Ferrer.
Strategic Transactions - February 24, 2018
Mundipharma acquires Tolmar Australia
Mundipharma Pty. Ltd. acquired Tolmar Australia Pty. Ltd., a division of Tolmar Holding with offerings for prostate cancer. The purchase price was not disclosed.
Strategic Transactions - February 24, 2018
Advaxis nets $18.8mm through public offering
Advaxis Inc. (Listeria-based immunotherapies for cancer) netted $18.8mm through the public sale of 10mm common shares at $2. Projects that will benefit from the proceeds include axalimogene filolisbac (persistant, recurrent, or metastatic carcinoma of the cervix), ADXS-PSA for prostate cancer, ADXS-NEO, a neoantigen therapeutic for various cancers, and ADXS-HOT, targeting hotspot mutations in prevalent cancers including NSCLC.
Strategic Transactions - February 24, 2018
Biohaven applies Catalent's Zydis technology to rimegepant migraine candidate
Biohaven Pharmaceuticals Holding Co. Ltd. gained exclusive worldwide rights to use Catalent Inc's Zydis orally disintegrating tablet (ODT) technology in the development of Biohaven's rimegepant (BHV3000).
Strategic Transactions - February 24, 2018
Everest gets rights to Arena's ralinepag and etrasimod in Greater China
Arena Pharmaceuticals Inc. licensed Everest Medicines Ltd. exclusive rights to develop and commercialize ralinepag and etrasimod in China, Taiwan, Hong Kong, Macau, and South Korea.
Strategic Transactions - February 24, 2018
Everest Medicines gets $50mm in Series A financing from C-Bridge
Everest Medicines Ltd. raised $50mm in its Series A financing from C-Bridge Capital. The round could bring in up to $130mm.
Strategic Transactions - February 24, 2018
Everest Medicines gets exclusive Asian rights to Tetraphase's eravacycline
Tetraphase Pharmaceuticals Inc. licensed Everest Medicines Ltd. exclusive rights to develop and commercialize eravacycline in China, Taiwan, Hong Kong, Macau, South Korea, and Singapore.
Strategic Transactions - February 24, 2018
Public offering nets $165mm for Aimmune
Aimmune Therapeutics Inc. (food allergy immunotherapies) netted $165mm through a public offering of 5.5mm common shares at $32. Proceeds are earmarked for continued development, regulatory filings, and commercialization of lead candidate AR101 for peanut allergy. Funds will also support ongoing work on additional projects designed with the company's CODIT oral immunotherapy platform.
Strategic Transactions - February 24, 2018
Ascendis nets $211.5mm via follow-on offering of ADSs
Ascendis Pharma AS (rare diseases) netted $211.5mm through the follow-on public offering of 3.95mm American Depositary Shares priced at $57; each ADS represents one ordinary share. The company will use some of the proceeds for clinical development, regulatory, and commercialization activities for its TransCon growth hormone; for development of other rare disease endocrinology programs including TransCon PTH and TransCon CNP; and for R&D in new therapy areas.
Strategic Transactions - February 24, 2018
Kite gets rights to Sangamo's zinc finger nuclease platform; could pay $3bn
Gilead Sciences Inc. division Kite Pharma Inc. licensed exclusive rights to use Sangamo Therapeutics Inc.’s zinc finger nuclease (ZFN) technology for the development of new cell therapies for cancer.
Strategic Transactions - February 24, 2018
Kolmar Korea acquires CJ CheilJedang's CJ Healthcare
CRO Kolmar Korea Co. agreed to acquire CJ CheilJedang Corp.'s CJ Healthcare for KRW1.31tn ($1.22bn).
Strategic Transactions - February 24, 2018
Procept BioRobotics completes $118mm late-stage round
In what appears to be a Series E round, urology-focused Procept BioRobotics Corp. (minimally invasive water ablation therapy) raised $118mm in a financing led by new backer Viking Global Investors LP, which was joined by other new investor Perceptive Advisors and returning participants, including CPMG. The company will use the proceeds to fund worldwide commercialization of its Aquablation technology for benign prostatic hyperplasia (BPH). The company's robot-controlled AquaBeam waterjet-based prostate resection system, which incorporates the Aquablation platform, was cleared by the FDA via the de novo pathway in December 2017 (with an expected US launch in May 2018). The AquaBeam is already sold in Canada, Australia, New Zealand, and certain limited European markets.
Strategic Transactions - February 24, 2018

Prime Therapeutics Expanding Formulary Exclusion Program In 2018
The NetResults formulary contributed to a 0.2% decline in overall drug spending by the pharmacy benefit manager's commercial clients in...
Scrip - February 23, 2018
Pionyr Maps Tumor Microenvironment, Plans 'Surgical' Strikes
Emerging Company Profile: Pionyr Immunotherapeutics exec who once led early development for Merck's PD-1 inhibitor Keytruda explains the San Francisco...
Scrip - February 23, 2018
Pipeline Watch: Phase III Starts With Atezolizumab, CNTX-4975 And WTX101
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical...
Scrip - February 23, 2018
Jobs Go At Shield Therapeutics As Failed Study Fallout Hits
Shield Therapeutics is to slash its workforce and is considering a possible sale in the wake of a failed Phase...
Scrip - February 23, 2018
UCB Promotes 'Underappreciated' Pipeline In FY Results
UCB's pipeline will see advances across multiple therapy areas in 2018, including more emphasis on new epilepsy indications and...
Scrip - February 23, 2018
Richter Expects Esmya Sales To Drop 50% Following EU Restrictions Over Liver Concerns
Restrictions placed on the use of Gedeon Richter’s uterine fibroid drug Esmya by the European Medicines Agency could significantly dent...
Scrip - February 23, 2018
Endgame For Singh Bros As India’s Top Court Upholds $550m Daiichi Arbitration Panel Award
Tycoons Malvinder and Shivinder Singh have exhausted Indian legal avenues in their fight against enforcement of a Singapore arbitration panel...
Scrip - February 23, 2018

CDC Panel Backs Heplisav-B Use, May Consider Preferential Recommendation
Dynavax's hepatitis B vaccine could end up as preferred choice for certain groups once safety and cost-effectiveness studies are completed.
The Pink Sheet - February 23, 2018
US FDA Learns 'Lessons Of History,' Takes Opioid Fight To Gabapentinoids
Agency investigating potential misuse and abuse of gabapentinoids, which CDC had recommended as alternative to opioids, in latest twist to...
The Pink Sheet - February 23, 2018
ANDA Pre-Submission Meetings A 'Challenge' To Integrate Into Development Timelines
US FDA officials appears worried about workload created by product development and pre-submission meetings for complex generics.
The Pink Sheet - February 23, 2018
Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The Pink Sheet - February 23, 2018
US/EU Inspections MRA: Lessons Learned And Challenges Ahead for FDA
Regulators in the US are finding it easier to assess the capability of European inspectorates under the landmark mutual recognition...
The Pink Sheet - February 23, 2018

Biopharma Quarterly Deal-making Statistics, Q4 2017
Biopharma financing finished off 2017 strong with a total value of $14.5 billion in Q4, led again by FOPOs. CVS'...
IN VIVO - February 21, 2018
GE Healthcare’s New Value Proposition: The Strategic Language Of Software
For an industry whose central structural dilemma is the slow pace of progress from bench to bedside, GE stands out...
IN VIVO - February 21, 2018

'Alice' In Patent Land: Finding Patentable Digital Health Innovations Is No Easy Task
While the mobile health sector and digital health in general is poised for a major boom, a 2014 case, Alice...
Medtech Insight - February 23, 2018
Medicare Drops Registry Requirement In ICD Coverage Policy And Adds 'Shared Decision-Making'
The new Medicare coverage policy for implantable cardioverter defibrillators, the first revision since 2005, incorporates MRI-compatible devices, tweaks some of...
Medtech Insight - February 23, 2018
AUDIO: Device Week, Feb. 23, 2018 – Down The Patent Hole With 'Alice'
Following a major Supreme Court patent case in 2014 that set a test for what is and is not patentable...
Medtech Insight - February 23, 2018
How Notified Body Notifications Could Handicap Parts Of The Medtech Industry
EU industry association MedTech Europe explains how the first-come, first-served approach to notified body notification threatens to disadvantage some in...
Medtech Insight - February 23, 2018
Eurasian Union Medtech Harmonization Likely To Be Delayed, Says Russian Industry Group
The January 2022 entry-into-force date of a Eurasian Economic Union-wide regulatory system dominates thinking in Russia and the other EAEU...
Medtech Insight - February 23, 2018
QUOTED. Feb. 23, 2018. Anthony Arnold.
Anthony Arnold, CEO of device-maker SetPoint, says the drug industry is underestimating what patients really want when it comes to...
Medtech Insight - February 23, 2018

P&G Trims Media Spending, Gets 'Lean' From Production To Market
P&G reduces "media waste" by 20% in 2017 and sees further cost-reduction opportunities through private marketplace deals with media companies...
The Rose Sheet - February 23, 2018
GNC Credit, Herbalife Q4, Industry Summit: Health And Wellness News
GNC approaches closing $300m Hayao investment with lenders' OK to re-work loans; Herbalife back to sales growth and prepares for...
The Rose Sheet - February 23, 2018
Senate Health Committee Releases Cosmetics Reform Discussion Draft
The committee's discussion draft of cosmetics reform legislation combines elements of the proposed Personal Care Products Safety Act and FDA...
The Rose Sheet - February 23, 2018

Progentity completes $125mm Series B round
Molecular diagnostics firm Progenity Inc. (women's health, reproductive medicine, and oncology testing) raised $125mm in a Series B round of equity and debt led by a fund managed by returning backer Athyrium Capital Management.
Strategic Transactions - February 24, 2018
Counsyl completes $80mm late-stage round
DNA screening company Counsyl Inc. (prenatal testing, women's health, and hereditary disorders) completed an undisclosed late-stage round of $80mm from Perceptive Advisors.
Strategic Transactions - February 24, 2018
FOPO nets $282mm for Amicus
Amicus Therapeutics Inc. (therapies for rare metabolic conditions) netted $282mm in its follow-on public offering of 19.35mm common shares at $15.50. The company will use some of the proceeds for global commercialization of migalastat for Fabry's disease, to invest in manufacturing capabilities for its Phase II Pompe disease candidate ATB200, and for additional R&D and commercial activities.
Strategic Transactions - February 24, 2018
Series A lands €16mm for ABAC Therapeutics
Antibiotics developer ABAC Therapeutics raised €16mm ($19.8mm) in its Series A financing led by Pontifax, which was joined by Global Health Science Fund (formed by Quark Venture and GF Securities), Caixa Capital Risc, Debiopharm Innovation Fund (part of Debiopharm Group), and returning shareholder Grupo Ferrer.
Strategic Transactions - February 24, 2018
Mundipharma acquires Tolmar Australia
Mundipharma Pty. Ltd. acquired Tolmar Australia Pty. Ltd., a division of Tolmar Holding with offerings for prostate cancer. The purchase price was not disclosed.
Strategic Transactions - February 24, 2018
Advaxis nets $18.8mm through public offering
Advaxis Inc. (Listeria-based immunotherapies for cancer) netted $18.8mm through the public sale of 10mm common shares at $2. Projects that will benefit from the proceeds include axalimogene filolisbac (persistant, recurrent, or metastatic carcinoma of the cervix), ADXS-PSA for prostate cancer, ADXS-NEO, a neoantigen therapeutic for various cancers, and ADXS-HOT, targeting hotspot mutations in prevalent cancers including NSCLC.
Strategic Transactions - February 24, 2018
Biohaven applies Catalent's Zydis technology to rimegepant migraine candidate
Biohaven Pharmaceuticals Holding Co. Ltd. gained exclusive worldwide rights to use Catalent Inc's Zydis orally disintegrating tablet (ODT) technology in the development of Biohaven's rimegepant (BHV3000).
Strategic Transactions - February 24, 2018
Everest gets rights to Arena's ralinepag and etrasimod in Greater China
Arena Pharmaceuticals Inc. licensed Everest Medicines Ltd. exclusive rights to develop and commercialize ralinepag and etrasimod in China, Taiwan, Hong Kong, Macau, and South Korea.
Strategic Transactions - February 24, 2018
Everest Medicines gets $50mm in Series A financing from C-Bridge
Everest Medicines Ltd. raised $50mm in its Series A financing from C-Bridge Capital. The round could bring in up to $130mm.
Strategic Transactions - February 24, 2018
Everest Medicines gets exclusive Asian rights to Tetraphase's eravacycline
Tetraphase Pharmaceuticals Inc. licensed Everest Medicines Ltd. exclusive rights to develop and commercialize eravacycline in China, Taiwan, Hong Kong, Macau, South Korea, and Singapore.
Strategic Transactions - February 24, 2018
Public offering nets $165mm for Aimmune
Aimmune Therapeutics Inc. (food allergy immunotherapies) netted $165mm through a public offering of 5.5mm common shares at $32. Proceeds are earmarked for continued development, regulatory filings, and commercialization of lead candidate AR101 for peanut allergy. Funds will also support ongoing work on additional projects designed with the company's CODIT oral immunotherapy platform.
Strategic Transactions - February 24, 2018
Ascendis nets $211.5mm via follow-on offering of ADSs
Ascendis Pharma AS (rare diseases) netted $211.5mm through the follow-on public offering of 3.95mm American Depositary Shares priced at $57; each ADS represents one ordinary share. The company will use some of the proceeds for clinical development, regulatory, and commercialization activities for its TransCon growth hormone; for development of other rare disease endocrinology programs including TransCon PTH and TransCon CNP; and for R&D in new therapy areas.
Strategic Transactions - February 24, 2018
Kite gets rights to Sangamo's zinc finger nuclease platform; could pay $3bn
Gilead Sciences Inc. division Kite Pharma Inc. licensed exclusive rights to use Sangamo Therapeutics Inc.’s zinc finger nuclease (ZFN) technology for the development of new cell therapies for cancer.
Strategic Transactions - February 24, 2018
Kolmar Korea acquires CJ CheilJedang's CJ Healthcare
CRO Kolmar Korea Co. agreed to acquire CJ CheilJedang Corp.'s CJ Healthcare for KRW1.31tn ($1.22bn).
Strategic Transactions - February 24, 2018
Procept BioRobotics completes $118mm late-stage round
In what appears to be a Series E round, urology-focused Procept BioRobotics Corp. (minimally invasive water ablation therapy) raised $118mm in a financing led by new backer Viking Global Investors LP, which was joined by other new investor Perceptive Advisors and returning participants, including CPMG. The company will use the proceeds to fund worldwide commercialization of its Aquablation technology for benign prostatic hyperplasia (BPH). The company's robot-controlled AquaBeam waterjet-based prostate resection system, which incorporates the Aquablation platform, was cleared by the FDA via the de novo pathway in December 2017 (with an expected US launch in May 2018). The AquaBeam is already sold in Canada, Australia, New Zealand, and certain limited European markets.
Strategic Transactions - February 24, 2018
Back to the top Back to the top